{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:31:51Z","timestamp":1791570711768,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jtct.2026.05.033","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:37:06Z","timestamp":1779320226000},"page":"1352.e1-1352.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment Outcomes of Adult B-Cell Acute Lymphoblastic Leukemia with Post-Transplant Relapse in the Era of Immunotherapeutic Agents"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8550-4181","authenticated-orcid":false,"given":"Hiroaki","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8910-0021","authenticated-orcid":false,"given":"Yuho","family":"Najima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2635-3395","authenticated-orcid":false,"given":"Shinichi","family":"Kako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7780-4459","authenticated-orcid":false,"given":"Takayoshi","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9900-4421","authenticated-orcid":false,"given":"Akihiko","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Tanoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-1928","authenticated-orcid":false,"given":"Emiko","family":"Sakaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5163-0163","authenticated-orcid":false,"given":"Katsuhiro","family":"Shono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Yoshifuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3864-0823","authenticated-orcid":false,"given":"Makoto","family":"Onizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0973-6363","authenticated-orcid":false,"given":"Atsushi","family":"Jinguji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Toya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8661-3179","authenticated-orcid":false,"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8814-230X","authenticated-orcid":false,"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9827-8526","authenticated-orcid":false,"given":"Shun-ichi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4523-2994","authenticated-orcid":false,"given":"Shin-ichiro","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Aotsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Hagihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4866-9307","authenticated-orcid":false,"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.05.033_bib0001","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/jamaoncol.2017.5305","article-title":"Pediatric-inspired treatment regimens for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: a review","volume":"4","author":"Luger","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtct.2026.05.033_bib0002","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.72","article-title":"Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group","volume":"4","author":"Hayakawa","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2026.05.033_bib0003","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","article-title":"High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group","volume":"24","author":"Yanada","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.05.033_bib0004","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","article-title":"Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate","volume":"103","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.05.033_bib0005","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1182\/blood-2011-09-377713","article-title":"Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.05.033_bib0006","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1182\/blood-2014-09-599894","article-title":"Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia","volume":"125","author":"Dh\u00e9din","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.05.033_bib0007","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ajh.27237","article-title":"Utility of allogeneic stem cell transplantation for adult Ph+ALL with complete molecular remission","volume":"99","author":"Nishiwaki","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2026.05.033_bib0008","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s41409-018-0373-4","volume":"54","author":"Giebel","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.05.033_bib0009","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1182\/bloodadvances.2022008032","article-title":"Improvements in allogeneic hematopoietic cell transplantation outcomes for adults with ALL over the past 3 decades","volume":"6","author":"Nishiwaki","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.05.033_bib0010","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/leu.2011.351","article-title":"Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT","volume":"26","author":"Spyridonidis","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2026.05.033_bib0011","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.bbmt.2013.04.014","article-title":"Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation","volume":"19","author":"Poon","year":"2013","journal-title":"Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.05.033_bib0012","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.05.033_bib0013","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.05.033_bib0014","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2026.05.033_bib0015","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.bbmt.2019.04.010","article-title":"Blinatumomab for acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Stein","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.05.033_bib0016","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.05.033_bib0017","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1182\/bloodadvances.2022008981","article-title":"CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: Real-world data from Germany","volume":"7","author":"Bader","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.05.033_bib0018","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.05.033_bib0019","first-page":"825","article-title":"Consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.05.033_bib0020","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.05.033_bib0021","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/bmt.2016.130","article-title":"Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation","volume":"51","author":"Mohty","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.05.033_bib0022","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.05.033_bib0023","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data","volume":"21","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2026.05.033_bib0024","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1111\/cas.14167","article-title":"Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"110","author":"Akahoshi","year":"2019","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jtct.2026.05.033_bib0025","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely-available easy-to-use software \u201cEZR\u201d (Easy R) for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.jtct.2026.05.033_bib0026","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00277-020-04310-0","article-title":"Outcome predictors after retransplantation in relapsed acute lymphoblastic leukemia: a multicenter, retrospective study","volume":"100","author":"Mori","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2026.05.033_bib0027","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/bjh.15973","article-title":"Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"186","author":"Nagler","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2026.05.033_bib0028","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/s41409-025-02639-6","article-title":"Outcome of second allogeneic hematopoietic cell transplantation in adult patients with relapsed B-cell acute lymphoblastic leukemia in the era of new immunotherapeutic agents","volume":"60","author":"Kwag","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.05.033_bib0029","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","article-title":"Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"118","author":"Fo\u00e0","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.05.033_bib0030","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/jamaoncol.2019.5868","article-title":"Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial","volume":"6","author":"Shen","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtct.2026.05.033_bib0031","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.26816","article-title":"Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results","volume":"98","author":"Kantarjian","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2026.05.033_bib0032","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1001\/jama.2024.4783","article-title":"Ponatinib vs imatinib in frontline Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial","volume":"331","author":"Jabbour","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jtct.2026.05.033_bib0033","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.05.033_bib0034","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"issue":"Suppl. 1","key":"10.1016\/j.jtct.2026.05.033_bib0035","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/blood-2024-193946","article-title":"Sinusoidal obstruction syndrome in children with CD22+ B-cell precursors acute lymphoblastic leukemia (BCP-ALL) treated with inotuzumab ozogamicin in Trial ITCC-059: risk factors and outcomes","volume":"144","author":"Brivio","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.05.033_bib0036","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","article-title":"Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation","volume":"102","author":"Wadleigh","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.05.033_bib0037","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.05.033_bib0038","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.05.033_bib0039","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.05.033_bib0040","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1182\/blood.2024027500","article-title":"Up-front blinatumomab improves MRD clearance and outcome in adult Ph- B-lineage ALL: The GIMEMA LAL2317 phase 2 study","volume":"145","author":"Bassan","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.05.033_bib0041","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1200\/JCO.24.00490","article-title":"Inotuzumab ozogamicin and low-intensity chemotherapy in older patients with newly diagnosed CD22+ Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia","volume":"42","author":"Chevallier","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.05.033_bib0042","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ajh.27576","article-title":"Hyper-CVAD and sequential blinatumomab without and with inotuzumab in young adults with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia","volume":"100","author":"Kantarjian","year":"2025","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2026.05.033_bib0043","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1038\/s41375-021-01236-y","article-title":"Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed\/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy","volume":"35","author":"Hu","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2026.05.033_bib0044","doi-asserted-by":"crossref","first-page":"75.e1","DOI":"10.1016\/j.jtct.2023.10.004","article-title":"Practice preferences for consolidative hematopoietic stem cell transplantation following tisagenlecleucel in children and young adults with B Cell acute lymphoblastic leukemia","volume":"30","author":"McNerney","year":"2024","journal-title":"Transplant Cell Ther"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726004227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726004227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:58:02Z","timestamp":1791529082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726004227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2666636726004227"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.05.033","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Outcomes of Adult B-Cell Acute Lymphoblastic Leukemia with Post-Transplant Relapse in the Era of Immunotherapeutic Agents","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.05.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}